164 related articles for article (PubMed ID: 35933820)
1. Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy.
Tokutake T; Kasuga K; Tsukie T; Ishiguro T; Shimohata T; Onodera O; Ikeuchi T
Parkinsonism Relat Disord; 2022 Sep; 102():30-35. PubMed ID: 35933820
[TBL] [Abstract][Full Text] [Related]
2. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.
Hu X; Yang Y; Gong D
Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490
[TBL] [Abstract][Full Text] [Related]
4. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.
Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B
Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.
Hall S; Surova Y; Öhrfelt A; ; Blennow K; Zetterberg H; Hansson O
Mov Disord; 2016 Jun; 31(6):898-905. PubMed ID: 26878815
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
[TBL] [Abstract][Full Text] [Related]
7. Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again.
Compta Y; Painous C; Soto M; Pulido-Salgado M; Fernández M; Camara A; Sánchez V; Bargalló N; Caballol N; Pont-Sunyer C; Buongiorno M; Martin N; Basora M; Tio M; Giraldo DM; Pérez-Soriano A; Zaro I; Muñoz E; Martí MJ; Valldeoriola F
Parkinsonism Relat Disord; 2022 Jun; 99():33-41. PubMed ID: 35594661
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis.
Cong S; Xiang C; Wang H; Cong S
J Neurol; 2021 Aug; 268(8):2703-2712. PubMed ID: 32162061
[TBL] [Abstract][Full Text] [Related]
9. Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative.
Laurens B; Constantinescu R; Freeman R; Gerhard A; Jellinger K; Jeromin A; Krismer F; Mollenhauer B; Schlossmacher MG; Shaw LM; Verbeek MM; Wenning GK; Winge K; Zhang J; Meissner WG
Neurobiol Dis; 2015 Aug; 80():29-41. PubMed ID: 25982836
[TBL] [Abstract][Full Text] [Related]
10. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
[TBL] [Abstract][Full Text] [Related]
11. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.
Nabizadeh F; Pirahesh K; Valizadeh P
J Neurol; 2022 Sep; 269(9):4836-4845. PubMed ID: 35426534
[TBL] [Abstract][Full Text] [Related]
12. Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.
Singer W; Schmeichel AM; Shahnawaz M; Schmelzer JD; Boeve BF; Sletten DM; Gehrking TL; Gehrking JA; Olson AD; Savica R; Suarez MD; Soto C; Low PA
Ann Neurol; 2020 Sep; 88(3):503-512. PubMed ID: 32557811
[TBL] [Abstract][Full Text] [Related]
13. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
[TBL] [Abstract][Full Text] [Related]
14. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease.
Abdo WF; Bloem BR; Van Geel WJ; Esselink RA; Verbeek MM
Neurobiol Aging; 2007 May; 28(5):742-7. PubMed ID: 16678934
[TBL] [Abstract][Full Text] [Related]
15. Temporal trajectory of biofluid markers in Parkinson's disease.
Baek MS; Lee MJ; Kim HK; Lyoo CH
Sci Rep; 2021 Jul; 11(1):14820. PubMed ID: 34285331
[TBL] [Abstract][Full Text] [Related]
16. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
17. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
[TBL] [Abstract][Full Text] [Related]
18. Alpha-Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure.
Singer W; Schmeichel AM; Shahnawaz M; Schmelzer JD; Sletten DM; Gehrking TL; Gehrking JA; Olson AD; Suarez MD; Misra PP; Soto C; Low PA
Ann Neurol; 2021 Jun; 89(6):1212-1220. PubMed ID: 33881777
[TBL] [Abstract][Full Text] [Related]
19. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders.
Hall S; Janelidze S; Surova Y; Widner H; Zetterberg H; Hansson O
Sci Rep; 2018 Sep; 8(1):13276. PubMed ID: 30185816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
